Open-Label Extension, Single-Arm, Flexible-Dosing, Phase 3 Trial With CG5503 Extended-Release (ER) in Patients With Moderate to Severe Chronic Pain.
Phase of Trial: Phase III
Latest Information Update: 01 Oct 2015
At a glance
- Drugs Tapentadol (Primary)
- Indications Back pain; Osteoarthritis; Pain
- Focus Adverse reactions; Registrational
- Sponsors Janssen Research & Development
- 01 Oct 2015 Results published in the Clinical Therapeutics.
- 15 Sep 2009 Actual patient number (1166) added as reported by ClinicalTrials.gov.
- 15 Sep 2009 Actual end date (Jun 2009) added as reported by ClinicalTrials.gov.